chenodeoxycholic acid has been researched along with Dyslipidemia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Adorini, L; Jansen, E; Marchesi, JR; Marschall, HU; McDonald, JAK; McIlvride, S; Ovadia, C; Papacleovoulou, G; Pataia, V; Shapiro, D; Wahlström, A; Williamson, C | 1 |
| Aguilera, V; Ampuero, J; Bellido, F; Romero-Gómez, M; Sánchez-Torrijos, Y | 1 |
| Adinolfi, LE; Lonardo, A; Marrazzo, A; Maurantonio, M; Nascimbeni, F; Rinaldi, L | 1 |
| Briand, F; Brousseau, E; Burcelin, R; Quinsat, M; Sulpice, T | 1 |
| Kowdley, KV; Manne, V | 1 |
| Adorini, L; Bellafante, E; Fan, HM; Jansen, E; Jones, P; Marchesi, JR; Marschall, HU; McDonald, JAK; McIlvride, S; Nikolova, V; Shapiro, D; Wahlström, A; Williamson, C | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
3 review(s) available for chenodeoxycholic acid and Dyslipidemia
| Article | Year |
|---|---|
New therapeutic perspectives in non-alcoholic steatohepatitis.
Topics: Bariatric Surgery; Chenodeoxycholic Acid; Clinical Trials as Topic; Combined Modality Therapy; Diet, Mediterranean; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Dyslipidemias; Endoscopy; Exercise Therapy; Gastrointestinal Microbiome; Glucagon-Like Peptide-1 Receptor; Humans; Insulin Resistance; MAP Kinase Kinase Kinase 5; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity, Abdominal; Peroxisome Proliferator-Activated Receptors; Receptors, Cytoplasmic and Nuclear; Weight Loss | 2018 |
Nonalcoholic fatty liver disease: Evolving paradigms.
Topics: Biomarkers; Chenodeoxycholic Acid; Diabetes Mellitus, Type 2; Diagnostic Imaging; Diet, Reducing; Dyslipidemias; Exercise Therapy; Humans; Hyperuricemia; Hypoglycemic Agents; Liver; Liver Function Tests; Liver Neoplasms; Mass Screening; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Prevalence; Risk Assessment; Risk Factors; Vitamin E | 2017 |
Obeticholic acid in primary biliary cholangitis: where we stand.
Topics: Chenodeoxycholic Acid; Cholesterol, HDL; Dose-Response Relationship, Drug; Drug Labeling; Dyslipidemias; Humans; Liver Cirrhosis, Biliary; Nasopharyngitis; Pruritus; Receptors, Cytoplasmic and Nuclear; Treatment Outcome | 2019 |
4 other study(ies) available for chenodeoxycholic acid and Dyslipidemia
| Article | Year |
|---|---|
Obeticholic acid improves fetal bile acid profile in a mouse model of gestational hypercholanemia.
Topics: Animals; Bile Acids and Salts; Cecum; Chenodeoxycholic Acid; Cholestasis, Intrahepatic; Cholesterol 7-alpha-Hydroxylase; Dyslipidemias; Female; Gene Expression Regulation; Liver; Mice; Mice, Inbred C57BL; Pregnancy; Pregnancy Complications; RNA-Binding Proteins; RNA, Ribosomal, 16S | 2020 |
Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
Topics: Animals; Body Weight; CD36 Antigens; Chenodeoxycholic Acid; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Diet; Disease Models, Animal; Dyslipidemias; Gene Expression Regulation; Insulin Resistance; Liver; Male; Non-alcoholic Fatty Liver Disease; Rats; Receptors, LDL | 2018 |
Obeticholic acid ameliorates dyslipidemia but not glucose tolerance in mouse model of gestational diabetes.
Topics: Animals; Blood Glucose; Chenodeoxycholic Acid; Diabetes, Gestational; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Female; Glucose Intolerance; Insulin Resistance; Lipid Metabolism; Male; Mice; Mice, Inbred C57BL; Pregnancy; Pregnancy Complications | 2019 |
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |